VRTX

How is VRTX doing right now?

In plain terms: VRTX is 12.3% below its highest-ever price. Dipsern checks every past time it was this far down and grades how the next 90 days usually went.

As of the latest market close, Vertex Pharmaceuticals (VRTX) is trading in a moderate correction, 12.3% below its all-time high at $453.17. Corrections in this band are common during macro repricings (rate scares, sector rotations, earnings shocks). The question is whether the cause is durable or transient.

What history says at this drawdown

VRTX reaches this drawdown band repeatedly in its history (680 observations), which is a large sample for the segmentation engine to compute a stable median forward return. The engine uses a rolling 90-day window and gives more weight to recent years — this lets the signal adapt to regime changes (e.g., post-COVID volatility) without losing the long-run base rate.

What this means for VRTX

For US large-caps, drawdowns of 20-30% are typically driven by macro repricing (rates, earnings, sector rotation). Single-name 50%+ drawdowns are usually structural — the signal alone won't tell you which, but the segments table will show whether prior episodes recovered. This is the band where most successful "buy the dip" strategies have historically operated. The median forward return here for VRTX is in the full app, alongside the segment-level win rate.